Viking Therapeutics, Inc.
VKTX
Jodie situation report
Viking Therapeutics, Inc.'s move is being confirmed by its market group.
VKTX accounts for 24.3% of the group's measured movement across 6.0 effective names. raw member direction is mixed; 6 of 8 SPY-adjusted paths align to the downside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
VKTX was the first measured mover. VKTX crossed its material path threshold at 11:05 ET. SMMT, ROIV, IBRX followed.
5 of 8 members in Gene Editing Therapies are active. 0 of 8 disclosed connections are confirming.
- At least 6 of 8 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as RLYB begins moving with the group.
Invalidation: The live read weakens if participation falls to 2 of 8 members or fewer.
Who this business touches
The relationships behind VKTX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
LGNDLigand Pharmaceuticals IncorporatedpartnerOct 23, 2025 ▾
“Our primary use of cash is to fund operating expenses, which to date have consisted of the cost to obtain the license of intellectual property from Ligand, certain research and development expenses related to furthering the development of VK2735 subcutaneous,…”
AMGNAmgen Inc.competitorApr 30, 2026 ▾
“We are also aware of several programs targeting obesity that are in the late development stage that will compete against VK2735, if approved, including CagriSema from Novo Nordisk A/S, retatrutide from Eli Lilly and Company, survodutide (BI 456906) from Boehr…”
Depended on by
PTGXProtagonist Therapeutics, Inc.partnerFeb 25, 2026 ▾
“VK2735 (Viking Therapeutics) is a dual GLP-1/GIP receptor agonist in Phase 3 development for subcutaneous administration, with an oral formulation in mid-stage clinical development.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 10 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
VKTX is currently a Early Follower in the organic co-movement group Gene Editing Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.